Intra-Cellular Therapies Accounts Payable

The latest accounts payable for ITCI is $26M as of December 2024. That compares with $11M in the prior-year period — up 127.7% year over year. Investors often review this figure alongside Intra-Cellular Therapies's historical trend and sector peers before judging valuation or financial health.

Over the past year, ITCI's accounts payable moved from $11M to $26M — a 127.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Intra-Cellular Therapies's operating scale or balance-sheet position.

A accounts payable figure of $26M for ITCI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ITCI's accounts payable ($26M), review year-over-year change from $11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Intra-Cellular Therapies's accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.